Filing summary
Entity discrepancy: The request identifies Traws Pharma, Inc., but the supplied 10-Q is for Onconova Therapeutics, Inc. (Nasdaq: ONTX). This summary reflects the filing provided, for the quarter ended June 30, 2023, filed August 14, 2023. Financial statements are unaudited.
Business context and reporting period
Onconova is a clinical-stage biopharmaceutical company developing oncology therapeutics. Its programs include narazaciclib, a multi-kinase inhibitor, and rigosertib, being evaluated in several cancer settings. The filing reports results for the three and six months ended June 30, 2023, compared with the same periods in 2022.
Financial performance and liquidity
| Metric | Q2 2023 | Q2 2022 | Six months 2023 | Six months 2022 |
|---|---|---|---|---|
| Revenue | $57,000 | $57,000 | $113,000 | $113,000 |
| Research and development | $2.456 million | $2.038 million | $6.536 million | $4.040 million |
| General and administrative | $2.211 million | $2.139 million | $4.324 million | $4.325 million |
| Total operating expenses | $4.667 million | $4.177 million | $10.860 million | $8.365 million |
| Net loss | $4.250 million | $4.024 million | $10.025 million | $8.146 million |
| Basic and diluted loss per share | $0.20 | $0.19 | $0.48 | $0.39 |
| Operating cash used | Not stated for quarter | Not stated for quarter | $9.033 million | $8.510 million |
Revenue was entirely from recognition over time of a deferred upfront license payment under the SymBio collaboration. The filing does not present meaningful operating margins given the company’s minimal revenue and operating losses.
At June 30, 2023, cash and cash equivalents were $29.729 million, down from $38.757 million at December 31, 2022. Working capital was $21.8 million; total assets were $30.468 million and total liabilities were $11.570 million. The balance sheet reports no interest-bearing debt. Liabilities mainly comprised accounts payable, accrued expenses, and deferred revenue. Accumulated deficit was $473.708 million.
Material changes versus prior comparable periods
- Six-month R&D expense rose 62% to $6.536 million, primarily due to higher narazaciclib clinical development, consulting, and manufacturing costs. Q2 R&D increased 21% year over year.
- Six-month net loss widened to $10.025 million from $8.146 million, despite higher other income, which primarily reflected increased interest income.
- Six-month operating cash use increased to $9.033 million from $8.510 million. Cash fell by $9.028 million during the first half of 2023.
- G&A was essentially unchanged for the first half. Common shares outstanding were 20,977,625 at June 30, 2023, compared with 20,925,992 at year-end 2022.
Outlook, developments, and risks
- Going concern and financing: Management expects existing cash to fund ongoing trials and operations into the second quarter of 2024, but says it is insufficient to support operations for at least 12 months after issuance of the statements. The company concludes substantial doubt exists about its ability to continue as a going concern. It plans to seek equity and other financing, strategic alliances, and business-development opportunities; success and terms are uncertain.
- Spending outlook: The company expects 2023 cash expenditures to exceed 2022 levels, citing narazaciclib trials and increased clinical and regulatory headcount. Additional in-licensing could increase costs.
- Clinical programs: The first patient in a Phase 1/2a narazaciclib-plus-letrozole trial for recurrent metastatic low-grade endometrioid endometrial cancer was dosed in May 2023. The US narazaciclib Phase 1 study had completed enrollment in the 200 mg cohort, with one dose-limiting toxicity observed; the 240 mg cohort was ongoing, also with one observed dose-limiting toxicity. Rigosertib studies in KRAS-mutated cancers and RDEB-associated squamous cell carcinoma continued enrolling or progressing. RDEB-SCC efficacy observations described in the filing involve only two patients; the company plans to design a registrational trial following an FDA meeting.
- Financing access and listing: The company’s $25 million at-the-market equity agreement and related shelf registration expired in May 2023; no shares were sold under the agreement during the first half of 2023. The filing warns that future Nasdaq noncompliance could result in delisting and impair liquidity and capital-raising ability. The company reported compliance as of August 14, 2023, while noting prior minimum-bid-price compliance issues.
- Other disclosures: No material pending legal proceedings were reported. Management stated disclosure controls were effective and reported no material change in internal control over financial reporting during the quarter.
Important facts for investors to verify
- Confirm the intended issuer: the supplied filing is Onconova Therapeutics, Inc., not Traws Pharma, Inc.
- Monitor available cash, operating cash burn, and the company’s ability to secure financing before the projected second-quarter 2024 cash horizon.
- Track clinical-trial enrollment, safety findings, and whether early rigosertib observations are replicated in larger studies.
- Verify the status and terms of any replacement financing, collaboration, or licensing arrangements, and assess potential dilution or rights granted.
- Check subsequent Nasdaq listing status and any changes to the company’s clinical plans or going-concern assessment.